Chimeric Antigen Receptor T-Cell Therapy: Neurocognitive Effects and Patient-Reported Outcomes
The purpose of this study is to assess self-reported side-effects and neurocognitive (brain, mood, and thinking) functioning among patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. In order to study side-effects and functioning among people receiving CAR-T therapy, the study team will collect and compare information from participants who receive CAR-T therapy as well as from people who have no history of cancer.
The goal of the current study is to better understand changes in PROs and cognition in 204 adult CAR T-cell therapy recipients (CART+) compared to 102 non-cancer controls (CA-) frequency-matched on age, biological sex, and education. Aims are as follows: Aim 1: To examine baseline differences and longitudinal changes in patient-reported outcomes and cognition in CAR T-cell therapy recipients and non-cancer controls. Aim 2: To identify demographic, contextual, and clinical risk factors associated with worse cognition in CAR T-cell therapy recipients compared to non-cancer controls. Aim 3: To determine behavioral protective factors associated with better cognition among CAR T-cell therapy recipients and non-cancer controls.
- Inclusion Criteria:
- At least 18 years of age
- Diagnosed with hematologic cancer (e.g.,diffuse large B-cell lymphoma, multiple myeloma),
- Scheduled to receive CAR T cell therapy at Moffitt Cancer Center
- Have internet access at home
- Able to speak and read English,
- Able to provide written informed consent.
- Exclusion Criteria:
- Patients with documented or observable neurological disorder (e.g., Parkinson’s disease, dementia), or uncontrolled sleep disorder (e.g., sleep apnea, restless leg syndrome)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.